WDR42C Inhibitors
WDR42C inhibitors encompass a variety of chemical entities that exert their inhibitory effects through distinct yet interrelated biochemical mechanisms. Inhibitors that target kinase activity, for instance, disrupt a multitude of signaling pathways that converge on the functional activity of WDR42C. By inhibiting kinases essential for signal transduction, these compounds ensure that WDR42C's role in cellular communication is diminished. Kinase inhibitors achieve this by blocking the phosphorylation events crucial for the activation of pathways like PI3K/AKT and MAPK/ERK, which are vital for cell cycle control, proliferation, and cellular stress responses, where WDR42C is known to have implications. On the other hand, inhibitors of the mTOR pathway present a different mode of action by directly curbing the mTOR signaling that regulates protein synthesis, thereby influencing WDR42C's involvement in growth and metabolism.
Additional classes of WDR42C inhibitors function by altering the cellular environment and the stability of regulatory proteins. Compounds that impair the function of the proteasome system indirectly affect WDR42C by impeding the degradation of proteins that may regulate WDR42C's activity. By preventing proteolysis, these inhibitors can lead to an accumulation of regulatory proteins, subsequently influencing the pathways in which WDR42C participates. Furthermore, inhibitors that disrupt calcium homeostasis or hedgehog signaling pathways can indirectly lead to the inhibition of WDR42C by affecting calcium-dependent mechanisms or by hindering processes related to cellular growth and differentiation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that acts on various kinases which are essential for multiple signaling pathways, leading to the inhibition of WDR42C's functional activity in signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphatidylinositol 3-kinase (PI3K) inhibitor that impedes the PI3K/AKT pathway, which indirectly may result in the inhibition of WDR42C by affecting downstream signaling processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, leading to the blockade of the ERK pathway; WDR42C function is inhibited as a result of the interruption of this signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that disrupts the mTOR signaling pathway, leading to decreased protein synthesis and ultimately inhibiting the function of WDR42C in growth and metabolism regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), altering transcription factor activity and cellular responses, which indirectly inhibits WDR42C's role in cellular stress responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor which modulates inflammatory cytokine production and cellular stress responses, indirectly affecting WDR42C's involvement in these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific inhibitor of MEK that prevents the activation of MAPK/ERK, subsequently leading to inhibition of WDR42C's function in cell cycle control and proliferation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that can block the PI3K/AKT/mTOR pathway, indirectly leading to inhibition of WDR42C by preventing the signal transduction required for its activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
An AKT inhibitor which impairs the PI3K/AKT signaling, thereby indirectly inhibiting WDR42C by interference in its associated signaling pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that prevents the degradation of regulatory proteins, indirectly inhibiting WDR42C's function by affecting proteostasis and signal transduction. | ||||||